Tempest Therapeutics hauls in $70 mln Series B
San Francisco-based Tempest Therapeutics, a biotechnology company, has closed $70 million in Series B financing. The investors included Versant Ventures, F-Prime Capital Partners, Quan Capital, Lilly Asia Ventures, Foresite Capital and Eight Roads Ventures.
29 March 2018•1 min read
